Study of biomarkers in liver cancer after surgery
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
This study looks at blood samples from liver cancer patients who had surgery to see if certain markers can help predict their long-term health and guide their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06382103 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze blood samples from patients with hepatocellular carcinoma (HCC) who have undergone surgical resection. It focuses on identifying circulating tumor DNA (ctDNA) and plasma protein levels to enhance the prediction of long-term prognosis and inform treatment options. By monitoring ctDNA and conducting plasma proteomic analysis, the study seeks to improve patient outcomes following surgery. The findings could lead to more personalized treatment strategies for HCC patients.
Who should consider this trial
Good fit: Ideal candidates include patients with a first diagnosis of hepatocellular carcinoma who are scheduled for surgical treatment.
Not a fit: Patients with secondary liver cancer, intrahepatic cholangiocarcinoma, or other concurrent malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide more accurate prognostic information and tailored treatment options for patients with hepatocellular carcinoma.
How similar studies have performed: Other studies have shown promise in using ctDNA and plasma proteomics for cancer prognosis, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a first diagnosis of HCC. * Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy. * Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level. Exclusion Criteria: * Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma. * Any other concurrent malignancy. * History of organ transplant or hepatic encephalopathy.
Where this trial is running
Shanghai
- Zhongshan Hospital Fudan University — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Huichuan Sun
- Email: sun.huichuan@zs-hospital.sh.cn
- Phone: +86-21-64041990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.